NOUBAR AFEYAN, a director at $MRNA, sold 23,853 shares of the company on 12-11-2025 for an estimated $703,305. We received data on the trade from a recent SEC filing. This was a sale of approximately 85.9% of their shares of this class of stock. Following this trade, they now own 3,924 shares of this class of $MRNA stock.
$MRNA Insider Trading Activity
$MRNA insiders have traded $MRNA stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:
- NOUBAR AFEYAN sold 23,853 shares for an estimated $703,305
- ABBAS HUSSAIN sold 504 shares for an estimated $13,910
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MRNA Hedge Fund Activity
We have seen 277 institutional investors add shares of $MRNA stock to their portfolio, and 409 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 7,341,167 shares (-37.4%) from their portfolio in Q3 2025, for an estimated $189,622,343
- VOLORIDGE INVESTMENT MANAGEMENT, LLC removed 2,434,032 shares (-71.5%) from their portfolio in Q3 2025, for an estimated $62,871,046
- JANE STREET GROUP, LLC removed 2,402,567 shares (-63.5%) from their portfolio in Q3 2025, for an estimated $62,058,305
- NATIONAL BANK OF CANADA /FI/ added 2,112,644 shares (+356.7%) to their portfolio in Q3 2025, for an estimated $54,569,594
- MORGAN STANLEY added 1,858,694 shares (+22.9%) to their portfolio in Q3 2025, for an estimated $48,010,066
- D. E. SHAW & CO., INC. removed 1,317,181 shares (-17.6%) from their portfolio in Q3 2025, for an estimated $34,022,785
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 1,272,315 shares (+41.9%) to their portfolio in Q3 2025, for an estimated $32,863,896
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MRNA Analyst Ratings
Wall Street analysts have issued reports on $MRNA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 3 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Underperform" rating on 11/21/2025
- Piper Sandler issued a "Overweight" rating on 11/21/2025
- B of A Securities issued a "Underperform" rating on 11/10/2025
- JP Morgan issued a "Underweight" rating on 10/23/2025
- UBS issued a "Buy" rating on 10/23/2025
To track analyst ratings and price targets for $MRNA, check out Quiver Quantitative's $MRNA forecast page.
$MRNA Price Targets
Multiple analysts have issued price targets for $MRNA recently. We have seen 10 analysts offer price targets for $MRNA in the last 6 months, with a median target of $26.5.
Here are some recent targets:
- Andrew Tsai from Jefferies set a target price of $30.0 on 12/12/2025
- Matthew Harrison from Morgan Stanley set a target price of $28.0 on 12/12/2025
- Luca Issi from RBC Capital set a target price of $25.0 on 11/21/2025
- Mani Foroohar from Leerink Partners set a target price of $18.0 on 11/21/2025
- Edward Tenthoff from Piper Sandler set a target price of $63.0 on 11/21/2025
- Dimple Gosai from B of A Securities set a target price of $21.0 on 11/10/2025
- Gena Wang from Barclays set a target price of $25.0 on 11/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
